National Cancer Institute (NCI): Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 131 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with National Cancer Institute (NCI) as lead sponsor. 10 are open to participants now and 27 have results posted.

Phase 1 90Phase 2 37Phase 3 3No phase 12(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00049569Not applicable
• Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT00042796Phase 1
• Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory LymphomaTerminatedNCT00036855Phase 1
• Eligibility Screening for a NCI Pediatric Oncology Branch Research StudyCompletedNCT00026780
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic LeukemiaCompletedNCT00022737Phase 3
• Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00019708Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00017472Phase 1
• Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00016302Not applicable
• Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute LeukemiaCompletedNCT00016016Phase 1/2
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00006473Phase 2
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
• Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous TreatmentCompletedNCT00005811Phase 2
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00004862Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or LymphomaCompletedNCT00003970Phase 1
• 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT00003837Not applicable
• 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00003545Phase 2
• Raltitrexed in Treating Children With Refractory Acute LeukemiaCompletedNCT00003528Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
• 506U78 in Treating Patients With Refractory Hematologic CancerCompletedNCT00002970Phase 2
• Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic LeukemiaCompletedNCT00002704Phase 2
• A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With LeukemiaCompletedNCT00001689Phase 1